Zhou Zou

Zhou Zou

Auto-generated profile, based on publicly available information

Zhou Zou

Department of Biomedical Engineering, Southern University of Science and Technology, Shenzhen, Guangdong, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2020 in Biomicrofluidics
Verified
Journal Article
Open access
PDF file
ZCZhengkun Chen
Zhengkun Chen
KJKUAN JIANG
KUAN JIANG
ZZZhou Zou
Zhou Zou
XLXiaohe Luo
Xiaohe Luo
CLChwee Teck Lim
Chwee Teck Lim
CWCHUNYI WEN
CHUNYI WEN
Under internal or external insults such as aging and oxidative stresses, cells are induced into a senescent state and stop cellular division permanently. As senescent cells (SnCs) accumulate, the regeneration capacity of biological tissue would be compromised, which has been found to be associated with a plethora of age-related disorders. Therefore, isolating SnCs becomes necessary. To address the lack of effective surface markers for SnCs isolation, a label-free microfluidic device was proposed in this paper, in which a spiral microchannel was deployed to isolate SnCs based on their size differences. We adopted a well-received cellular senescence model by exerting excessive oxidative stress to murine mesenchymal stem cells. This model was then validated through a series of SnCs characterizations including size measurement, p16INK4a expression level, senescence-associated beta-galactosidase, and doubling time. The senescence chip demonstrated an efficiency of 75% and viability over 85% at a flow rate of 5 ml/min. The average cell size from the inner outlet was 5 μm larger than that from the outer outlet. The isolated cells had a sixfold higher p16INK4a expression level. Overall, the chip had an area under curve of 0.719 in the receiver operating characteristic analysis, showing decent performance in sorting SnCs. By having the ability to perform size-based sorting at a high flow rate, such a microfluidic device can provide high-throughput and label-free isolation of SnCs. To further improve the isolation performance, the device can be modified to introduce additional physical biomarkers of SnCs such as stiffness. This device poses a good potential in purification for cytotherapy or estimation of biological age.

18 February 2026 in Journal of Orthopaedic Translation
Verified
Journal Article
Open access
ZZZhou Zou
Zhou Zou
WGWeiyuan Gong
Weiyuan Gong
XLXuan Lu
Xuan Lu
YZYuqi Zhang
Yuqi Zhang
MAManting Au
Manting Au
CWCHUNYI WEN
CHUNYI WEN
Stem cells residing in the perivascular niche are critical for skeletal homeostasis. Vascular endothelin-1 (ET-1) controls stem cell fate in development, but its role in the exhaustion of skeletal stem cells (SSCs) and subsequent bone degeneration in osteoporosis remains poorly understood. This study aimed to determine whether ET-1 signalling drives SSCs senescence and to elucidate the underlying mechanisms. We utilised a combination of human single-cell RNA sequencing datasets, murine models of ageing and ovariectomy (OVX), and an endothelial-specific ET-1 overexpression transgenic (TET-1) mouse model. In vitro studies on mesenchymal stem cells (MSCs) employed ET-1 challenge with and without receptor-specific antagonists (BQ123 for ETAR, BQ788 for ETBR). The mechanism was further probed using transcriptomic profiling and validated in vivo through Prx1+ SSCs-specific ETBR knockout (Prx1-Cre;ETBRfl/fl) and pharmacological inhibition with the ETBR antagonist BQ788. In aged and OVX mice, ETBR expression was significantly upregulated in SSCs concurrent with bone loss. Transgenic ET-1 overexpression recapitulated an aged bone phenotype, inducing SSCs senescence and accelerating bone loss. In vitro, ET-1 triggered MSCs senescence and reactive oxygen species (ROS) accumulation. Such effects were specifically abrogated by ETBR, but not ETAR. Transcriptomic analysis revealed that ET-1/ETBR signalling synergistically dysregulates the PI3K-AKT and p53 pathways to orchestrate senescence. Critically, both genetic knockout of ETBR in Prx1+ SSCs and pharmacological inhibition with BQ788 mitigated oxidative stress, reduced cellular senescence, and preserved bone mass in OVX and aged mice. This study identified the ET-1/ETBR signalling axis as a critical driver of osteoporosis by promoting ROS-mediated SSCs senescence. We established a link between vascular ageing and skeletal decline. This study positioned ETBR blockade as a promising novel therapeutic strategy for osteoporosis. By targeting the upstream driver of SSCs exhaustion, ETBR inhibition offers a potential paradigm shift from palliative care to proactive rejuvenation of the osteogenic niche. This approach could counteract both postmenopausal and age-related bone loss by restoring the bone-forming potential of the skeleton, addressing a significant unmet clinical need.